FDA Approves ADHD Treatment Mydayis


The mixed amphetaminies salts formulation included 16 clinical trials results in its application.

The US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) of mixed salts of a single-entity amphetamine product (MYDAYIS) for attention-deficit/hyperactivity disorder (ADHD).

Mydayis, a long-acting, triple-bead, mixed amphetamine salts formulation, is a planned once-daily ADHD treatment for adult and children patients ages 13 years and older.

The submitted NDA for the treatment featured 16 clinical studies, including SHP465-305 — a short-term efficacy and safety study in pediatric ADHD patients aged 6-17 that returned positive results in June 2016.

Adolescent and adult clinical studies of Mydayis also reported statistically significant differences versus placebo at 16 hour post-dosing periods, with onset of action starting 2 or 4 hours post-dosing, as measured by the Permanent Product Measure of Performance (PERMP) scale.

The mixed salts formulation treatment is Irish-headquartered biopharmaceutical company Shire's most recent innovation in 2 decades of ADHD treatment support, Flemming Ornskov, MD, MPH, chief executive officer of Shire, said.

"It’s a testament to Shire’s commitment to helping support the evolving needs of appropriate patients with ADHD,” Flemming said. “With this approval, we hope to help patients who need a once-daily treatment option."

Adverse effects reported in Mydayis phase III studies included insomnia, decreased appetite, dry mouth, decreased weight, increased heart rate, and more, in all patient age groups.

Andrew J. Cutler, MD, is executive vice president and chief medical officer at Meridien Research and an investigator in the Mydayis clinical trials. He noted many patients living with ADHD are managing symptoms across a wide range of settings.

"Patients have individual needs and may respond differently to treatments, so it is important for healthcare professionals to have multiple options," Cutler said. "It’s rewarding to work with Shire to provide a new treatment option that may help appropriate patients with ADHD.”

Shire noted in a press release regarding the approval that Mydayis, as an amphetamine-containing medicine, has a high chance for abuse in patients and can lead to physical and psychological dependence.

Related Coverage

FDA Approves ADHD Treatment Cotempla XR-ODT

Study Finds Link Between Alzheimer's, Bipolar Disorder, and HCV

DAA Treatment for Patients with HCV Show Promise

Related Videos
Bhanu Prakash Kolla, MBBS, MD: Treating Sleep with Psychiatric Illness
Awaiting FDA Decision on MDMA Assisted Therapy, with Bessel van der Kolk, MD
Bessel van der Kolk, MD: The Future of MDMA Assisted Therapy in PTSD
Bessel van der Kolk, MD: What MDMA-Assisted Therapy Taught us About PTSD
Why Are Adult ADHD Cases Climbing?
Depression Screening: Challenges and Solutions at the Primary Care Level
HCPLive Five at APA 2024 | Image Credit: HCPLive
John M. Oldham, MD: A History of Personality Disorder Pathology
Franklin King, MD: Psychedelic Therapy History, Advances, and Hurdles
Robert Weinrieb, MD: Psychiatry-Hepatology Approach for Alcohol-Related Liver Disease
© 2024 MJH Life Sciences

All rights reserved.